NurExone Biologic Inc. (TSXV:NRX) (FSE:J90), a biopharmaceutical company developing biologically guided exosome therapy for patients with traumatic spinal cord injuries, has announced that it has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone’s first exotherapy product, after receiving a written response from the FDA on Aug. 29.
This is sponsored content issued on behalf of NurExone Biologic Inc., please see full disclaimer here.
Join the discussion: Find out what everybody’s saying about this stock on the NurExone Biologic Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
